trial start early 2017 march 2017 group peking university beijing hopes start clinical trials crispr cancers trials not approval funding lu trial injections participants supposed begin august date pushed lu says culturing amplifying cells took longer expected team ran china october holidays researchers removed immune cells recipient blood disabled gene combines dna cutting enzyme molecular guide programmed tell enzyme precisely cut disabled gene codes protein pd-1 normally puts brakes cell immune response cancers advantage function proliferate lu team cultured edited cells increasing number injected patient metastatic non small cell lung cancer hope pd-1 edited cells attack defeat cancer lu says